Strasbourg, France, 26 March 2024 – Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production. The new, ready-to-use plasmid is available off-the-shelf to complement the recent launch of pPLUS AAV-Helper in September 2023. Further launches of other pPLUS® RepCap plasmids to address the range of AAV serotypes will happen throughout 2024.
“In 2020, we made a commitment to evolve into a leading delivery supplier with capabilities across the expanding range of modalities in the market. Since then, the portfolio has steadily expanded for transfection reagents, and now we are making our ambition to become a key supplier of critical raw materials for AAV production clear,” Roel Gordjin, Chief Commercial Officer commented. “We have been out in the market speaking with existing and potential clients about what they need most and are well suited to meet those needs. In the AAV space we will be one of very few suppliers able to provide a complete pDNA portfolio, making us a logical first call for AAV manufacturers in their projects from research to commercial use.”
The pPLUS® AAV-RC2 plasmid is available on demand, with all manufacturing completed in house at the Xpress Biologics GMP compliant facility in Belgium to ensure quality and supply chain security.
Visit the page to learn more about the pPLUS® AAV-RC2 plasmid, which officially became available on 25 March 2024.
About Polyplus
Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. The legacy nucleic acid delivery portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro® and FectoVIR®-AAV. In 2020, the company began focusing on upstream bioprocess economic optimization with the addition of custom plasmid vector design, GMP transfection reagent and plasmid manufacturing with an internalized supply chain designed to meet strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.
Media Contact Information:
Geraldine Guerin-Peyrou
Director of Marketing & Communication
marketing@polyplus-transfection.com